• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Joining the Imagenetix Scientific and Medical Advisory Board Are Robert B. Zurier, M.D. And William J. Kraemer, Ph.D.

Posted on: Thursday, 21 April 2005, 09:00 CDT

Imagenetix, Inc. (OTCBB: IAGX), www.imagenetix.net, an innovator of scientifically tested, natural-based, proprietary bioceutical products that enhance human health, announced today the addition of two distinguished doctors to the Imagenetix Scientific and Medical Advisory Board. These experts will lend guidance to the company's scientific research and provide counsel related to product development.

Bill Spencer, CEO of Imagenetix, said: "We are very pleased to welcome Robert Zurier, M.D., who is a highly respected researcher and an expert in rheumatoid arthritis and inflammation, as well as William Kraemer, Ph.D., who is also a highly respected researcher with expertise in Kinesiology, Physiology and Neurobiology. Scientific study design input from experts in inflammation, arthritis and musculoskeletal movement should add great value to the Imagenetix products including Celadrin(R), our most researched product to date. Celadrin(R) is currently being marketed as both a topical pain cream and dietary supplement for joint function and mobility. We will continue with studies on Celadrin(R) and look forward to the insights and input from these two additional experts."

Accepting seats on the Imagenetix Scientific and Medical Advisory Board are:

Robert B. Zurier, M.D., who has been Professor of Medicine and Chief of Rheumatology at the University of Massachusetts Medical School in Worcester since 1991. From 1980 to 1991 he was Professor of Medicine and Chief of Rheumatology at the University of Pennsylvania School of Medicine in Philadelphia. Dr. Zurier graduated from the University of Texas Southwestern Medical School in Dallas, and trained in Internal Medicine at Boston City Hospital. He practiced general internal medicine in Holden, MA, for three years before training in clinical and research rheumatology at NYU-Bellevue Medical Center in New York City.

Dr. Zurier's research has focused on mechanisms of inflammation, especially as they relate to patients with arthritis and lupus. His basic studies of prostaglandins led to clinical trials using marine and botanical oils to treat patients with rheumatoid arthritis. Dr. Zurier's research has been funded by the National Institutes of Health since 1974. His accomplishments have been recognized by receipt of a Guggenheim Fellowship, designation as a Master of the American College of Rheumatology, and inclusion in "Best Doctors in America."

William J. Kraemer, Ph.D., who is a full professor in the Department of Kinesiology in the Neag School of Education working in the Human Performance Laboratory at the University of Connecticut (UCONN). He also holds an appointment as a full professor in the Department of Physiology and Neurobiology along with an appointment as a Professor of Medicine at the UCONN Health Center/School of Medicine. He also worked as Director of Research for three years in the Neag School of Education.

Since receiving his doctoral degree from the University of Wyoming in 1984, Dr. Kramer has authored and co-authored over 280 manuscripts in the scientific literature related to sports medicine and sports science. In addition, he has authored or co-authored 10 books in the areas of strength training and physiology of exercise. Dr. Kraemer serves on numerous scientific journal editorial boards and is the current Editor-In-Chief of the Journal of Strength and Conditioning Research, Associate Editor of Medicine and Science in Sports and Exercise and is on the Editorial Board for the Journal of Applied Physiology.

Dr. Kraemer is a member of the American Physiological Society and the Endocrine Society.

He is a Fellow in the American College of Sports Medicine (ACSM) and served as a member of the ACSM's Board of Trustees and Administrative Council. He is a past president of the National Strength and Conditioning Association (NSCA) and was honored by the NSCA with both their Outstanding Sports Scientist Award in 1992 and the NSCA's highest award, the Lifetime Achievement Award in 1994 for his contributions of bringing science into the field of strength and conditioning. He was named the "Educator of the Year" by the NSCA in 2002.

About Celadrin(R)

Celadrin(R) is a natural compound composed of esterified fatty acid carbons (EFACs) and other active synergists, and is a proprietary Imagenetix product. Celadrin(R) can be formulated into both pill and cream forms, and it can be used in formulations with other compounds to address the $22 billion joint health market. Celadrin(R) is currently available in oral form as a dietary supplement and as an over-the-counter topical cream at food, drug and mass retail stores.

In a double-blind, multi-center, placebo-controlled clinical trial of Celadrin(R), researchers examined the impact of an oral administration of Celadrin(R) on participants who were experiencing joint and mobility challenges of the knee. The placebo group and the Celadrin(R) group were evaluated at baseline, at 30 days, and at 68 days. Data from the study indicated that Celadrin(R) not only promoted joint flexibility, but also supported and promoted the ability to walk long distances.(1)

In an age-matched, double-blind study of patients diagnosed with osteoarthritis of the knee, researchers examined the impact of a topical administration of Celadrin(R) on participants. The placebo group and the Celadrin(R) group were evaluated at baseline, 30 minutes following initial treatment, and after 30 days, having applied the cream twice per day. Study data revealed that 100% of the participants using the Celadrin(R) cream experienced significant improvement in their ability to ascend and descend stairs, exhibit greater range of motion of the knee, ease of rising from a chair, functional mobility, and improved quality of life.(1) A most unique finding was that participants using the Celadrin(R) cream experienced an immediate effect from the treatment 30 minutes following the initial application.

(1) These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

About Imagenetix, Inc.

San Diego-based Imagenetix, Inc. (OTCBB: IAGX), www.imagenetix.net, is an innovator of scientifically tested, natural-based, proprietary bioceutical products that enhance human health. The Company develops, formulates and private-labels, proprietary, leading edge over-the-counter topical creams, skin care products and nutritional supplements to be marketed globally through multiple channels of distribution. Imagenetix also develops and formulates proprietary patentable pharmaceutical products.

Safe Harbor Statement

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company expects to file with the Securities Exchange Commission.

Source: Business Wire

More News in this Category